| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803089701015 | 308970101 | EYOPTO EY.DRO.SOL 2,5mg/ml BTx1 (αδιαφανές LDPE φιαλίδιο x 11ml που περιέχει 5ml διαλύματος) | 3.50 | 3.67 | 05.06 |
| 05/2018 | 2803089702012 | 308970201 | EYOPTO EY.DRO.SOL 5mg/ml BTx1 (αδιαφανές LDPE φιαλίδιο x 11ml που περιέχει 5ml διαλύματος) | 3.16 | 3.32 | 4.58 |
In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its opthalmic form it is used to treat open-angle and occasionally secondary glaucoma.
Like propranolol and nadolol, timolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle and beta(2)-receptors in the bronchial and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta(2)-blockade results in an increase in peripheral vascular resistance. The exact mechanism whereby timolol reduces ocular pressure is still not known. The most likely action is by decreasing the secretion of aqueous humor.
LD<sub>50</sub>=1190 mg/kg (oral, mice), LD<sub>50</sub>=900 mg/kg (oral, rat). Symptoms of overdose include drowsiness, vertigo, headache, and atriventricular block.
Bioavailability is about 60%
2.5-5 hours
Timolol and its metabolites are primarily excreted in the urine.